US FDA approves nintedanib (Ofev) for progressive Interstitial Lung Diseases (ILD)
The FDA has approved nintedanib oral capsules for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype. Nintedanib is currently in phase III development in the EU for this indication.
Source:
US Food and Drug Administration